Protein engineering is constrained by uncertainty, resulting in long development cycles, costly experimental iterations, and unpredictable success rates. At xyna.bio, we reduce design uncertainty, specializing in low-data environments and high-complexity protein systems where current approaches fall short. We are building the bridge between wet lab and dry lab by automating complex bioinformatics workflows. Our AI-driven platform leverages hybrid models that combine machine learning, physics-based simulation, and domain expertise to orchestrate end-to-end in silico pipelines. It forms the foundation of our entire workflow and is embedded across sequence design, structure prediction, dynamics simulation, and candidate optimization, enabling consistent, decision-ready insights at every stage. We deliver this through an intuitive, no-code platform that unifies these capabilities into seamless in silico workflows, complemented by custom model development and expert-designed experimental protocols, positioning us as an in silico CRO supporting early-stage R&D. We focus on accelerating biologics discovery, particularly nanobody (VHH) engineering, through automated screening, structural modeling, and developability assessment. By shifting critical decision-making into computation and enabling closed-loop integration between experimental and computational workflows, xyna.bio reduces development time, lowers costs, and increases success rates in early-stage R&D. We enable trusted, agentic hyperautomation through continuous quality assurance across the pipeline, complemented by robust data security and engineering aligned with the highest European standards. This is backed by decades of experience from our parent company, GIP Exyr GmbH, a developer of process automation software for leading telecommunications providers in the critical infrastructure sector. Our mission is to make advanced computational biology accessible, scalable, and fully integrated into modern life sciences innovation. Meet us at booth 3335.
Wales Cymru (Welsh Government)
Wales is a self-governing country of the UK and the Welsh Government is the devolved Government for Wales. The Welsh Government’s decision-making powers within a small and joined-up country mean we can act fast. They also mean we are responsible for our own economic development, so you won’t find a more pro-business Government anywhere. Wales has a strong industrial heritage that has shaped our confident, creative and ambitious economy of today. Wales means business.
Van Heron Labs
. | Van Heron Labs (VHL) The Cellular Intelligence Layer for Life Sciences Booth #1611 | vanheronlabs.com | contact@vanheronlabs.com — Van Heron Labs is transforming how biological processes are designed, optimized, and scaled. VHL has built the most powerful cellular intelligence engine ever created — the only end-to-end, multi-omic digital twin platform designed exclusively for cellular optimization. At the core of VHL’s platform is a proprietary system that decodes complete cellular biology — gene expression, metabolism, stress responses, and biomolecular needs across 17 molecular categories spanning thousands of compounds — and translates that data into a real-time biological digital twin. VHL identifies and predicts the impact of every critical biomolecule: metabolites, ions, trace metals, minerals, cofactors, growth factors, cytokines, ECM components, and more. The result: VHL customers see breakthrough improvements in titer, viability, potency, and manufacturability — faster and at a fraction of the cost of traditional R&D. Proven across cell therapy, biologics, precision fermentation, and more: T cell therapies (CD4/CD8, TIL, Treg): 80% improved viability, 40% increase in activation, FOXP3 stability for greater potency — saving $25K–$60K per batch iPSC programs: ~25 critical ingredients identified, many absent from any commercial media — 10X cheaper than internal R&D, 5 months faster to clinic MSC programs: ~30 critical ingredients identified, resolving stress pathways and improving scale-up reliability — unlocking $25–80M in potential new media product revenue HEK / bioprocessing: 40–200% proliferation improvement, 900% cell density gains with process optimization, 360% higher protein titer Microbial (E. coli, B. subtilis, P. aeruginosa): 200–400% proliferation increases, 200–360% higher titer, fully defined bioreactor media. How you can work with VHL: VHL offers four flexible engagement models — Analytics Only (1-week turnaround), Process Development Recommendations (1–2 weeks), Co-Development (3–10 weeks), and Strategic Partnerships for long-term innovation. All engagements begin with RNA-Seq or proteomics data and deliver interactive, publication-quality multi-omics reports, biological digital twins, and actionable recommendations your team can execute immediately. Backed by NVIDIA, Microsoft, and AWS, and trusted by dozens of life science companies, large and small. Who we’re looking to meet at BIO 2026: VHL is actively seeking strategic partnerships with CDMOs, CROs, reagent and culture media manufacturers, and asset-focused companies looking to improve manufacturing performance, reduce R&D burden, develop proprietary formulations, and unlock new revenue streams through the power of cellular intelligence. Want to connect before San Diego? Schedule a meeting or platform demo with CEO & Founder Rebecca Vaught, Ph.D. at calendly.com/rvaught-vanheronlabs/30min — or stop by Booth #1611 and meet us in person. We’d love to show you what cellular intelligence can do for your program.
SanaClis CRO
SanaClis CRO – Founded in 2000, SanaClis is a full-service global CRO with strong in-house clinical supply chain, logistics, and sourcing capabilities. We support clinical trials worldwide across the full study lifecycle and can operate as either a full-service or functional service provider, depending on sponsor needs. We have delivered clinical trial projects for sponsors ranging from virtual biotech to top 10 pharmaceutical companies, combining operational rigor with responsive execution and a focus on quality and predictable delivery. SanaClis provides CRO and clinical supply chain services across all therapeutic areas, with coverage across Europe (including the UK), USA (Americas) and Asia. We also bring deep operational experience in Central and Eastern Europe (CEE), supporting strong patient access and reliable site performance. To enable global distribution, SanaClis operates a network of privately owned, GMP- and GDP-certified depots strategically located worldwide. Our facilities support ambient and cold-chain storage, as well as packaging, labeling, and distribution services to protect product integrity throughout the IMP cold chain. CRO Services: Project Management, Clinical Monitoring, Site Management, Regulatory, Medical Writing, Data Management, Biostatistics, Pharmacovigilance, Medical Monitoring, Quality Management, Decentralized Trials. Clinical Supply Chain Services: Storage and Distribution, Secondary Packaging and Labelling, Global Strategic Sourcing, Qualified Person Services, Customs and Brokerage, SIMS – Inventory Management, Direct to Patient Services. Please reach out to Matt Delaney, Vice President of Business Development for the Americas region, email: matt.delaney@sanaclis.com or by phone at: 1 805 798-0060. Matt resides in San Diego, Ca.
Phastar
Phastar is an award-winning biometrics and data science CRO, trusted by pharma, biotech, and medical device companies worldwide. With a global team of data specialists, we bring expertise, precision, and pace to every trial—because behind every data point is a patient waiting for treatment. We don’t just deliver on-time high quality data; we partner with you to turn complexity into clarity. Leveraging best-in-class technology, AI-enhanced analytics, advanced statistical methods, and deep therapeutic expertise, we accelerate regulatory approvals, ensure compliance with global standards and seamlessly mitigate risk. Our proven track record in transforming complex data into clear, actionable intelligence enables you to accelerate drug development. With scalable, tailored solutions, we expedite trials—bringing life-changing therapies to patients faster.
PharSafer
Founded in 2003 by Dr Graeme Ladds, PharSafer® is a specialist Contract Research Organisation (CRO) in Global Clinical and Post Marketing Drug Safety, and Medical Services, with a wealth of experience in Pharmacovigilance, Auditing and Medical Affairs – and the various, numerous and extensive legal safety/medical obligations for licence holders to comply with – as well as Regulatory Strategy for the best methods for obtaining scientific advice concerning licence submissions and approvals. Together with our sister company which focuses on Training: SaPhar, PharSafer® continuously seeks new and innovative ways to provide added value for our global clients – going above and beyond expectations and optimising processes and procedures involved with clinical and post marketing drug safety and licencing approach. Our ability to offer first-class services in Pharmacovigilance, Regulatory Affairs, Training, Auditing, Medical Affairs and IT Informatics means that, for many clients, we operate as their Pharmacovigilance and Medical Departments – guiding them through the labyrinth of drug safety and medical legislation, all in the interests of ensuring patient safety and client compliance. We love what we do. We love finding solutions. Quite simply, we are by far… Your leading partner in Drug Safety. | PharSafer is a Global CRO specialising in Clinical & Post Marketing Pharmacovigilance; Medical Affairs; Training; Auditing; IT Informatics and Regulatory Intelligence. PharSafer have been operating for the last 23 years growing annually and helping take Companies from their clinical to post-marketing phases and many clients have been with us over 10 years now. PharSafer have attended over 100 inspections on behalf of clients to aid their compliance and ensure Regulatory Authorities are satisfied with the activities being performed. PharSafer are also an innovative Company designing validated and automated systems to provide cost-effective solutions for clients and ensure Regulatory compliant systems. Our client base is truly global being in all continents and for clients that have drugs; devices; vaccines; biologics; advanced therapies; biosimilars; herbal and cosmetics. Our Team within the Company are very experienced (many with over 15 years experience) aided by our sister training Company (SaPhar) to provide new updates for clients on country specific regulations with regular monthly contacts and comments going to all clients. We would be happy to engage with you and talk about product development; product expansions into new countries; product launches and perform all of the activities mentioned above. Please review of website and we look forward to engaging with you personally.
NEUROPHET
NEUROPHET Inc., Seoul, Republic of Korea, with expertise in neuroscience. We have been focusing on developing and providing innovative medical solutions for helping patients suffering from neurological diseases. To achieve the mission, we have applied state-of-the-art AI technologies to our expertise in neuroimaging, brain modeling and neuromodulation. We are conducting research in imaging-based biomarkers for Alzheimer’s disease (AD), which will be valuable tool for clinical trials (surrogate biomarker for drug response and disease progression) and companion diagnostics for AD therapeutics and furthermore, global standardization for AD staging and diagnostics. Neurophet provides medical-grade solutions approved by international regulatory bodies. | Neurophet Inc. develops advanced AI-powered neuroimaging solutions to enhance the diagnosis, monitoring, and treatment planning of neurological disorders. Its flagship products—AQUA AD, AQUA, and SCALE PET—deliver precise, quantitative insights into brain atrophy, lesion dynamics, and imaging biomarkers, including those associated with amyloid-targeted therapeutics (ATT) and amyloid-related imaging abnormalities (ARIA), through MRI and PET imaging. | Neurophet is a specialized company developing AI-powered brain imaging analysis solutions and therapeutic medical devices, covering the full cycle of neurological care — from MRI and PET analysis to wearable brain stimulation devices. We support medical institutions with AI-based imaging for diagnosis and treatment monitoring, and provide standardized central imaging services for global pharmaceutical clinical trials through our Imaging Core Lab (ICL). From the clinical frontline to global clinical trials, Neurophet is advancing as a global leader in neurological imaging analysis.